https://hingebio.com/2023/01/hinge-bio-expands-senior-management-team-to-drive-gem-dimera-programs-to-clinical-development/2023-05-30T21:33:07-07:00https://hingebio.com/2023/05/juha-punnonen-m-d-ph-d-joins-hinge-bio-as-chief-development-officer/2023-05-30T21:31:24-07:00https://hingebio.com/2024/04/hinge-bio-presents-preclinical-data/2024-04-07T21:36:00-07:00https://hingebio.com/2024/04/aacr-poster/2024-04-11T00:54:26-07:00https://hingebio.com/2024/08/hinge-bio-inc-chief-scientific-officer-daniel-capon-ph-d-to-present-its-gem-dimer-platform-technology-at-the-university-of-oxford-kennedy-institute-of-rheumatologys-annual-tra/2024-08-14T21:24:52-07:00https://hingebio.com/2022/03/topologically-engineered-antibodies-and-fc-fusion-proteins-a-new-class-of-multifunctional-therapeutic-candidates-for-sars-cov-2-cancer-and-other-disease/2024-08-15T07:30:18-07:00https://hingebio.com/2024/11/hinge-bio-presents-preclinical-data-from-its-gem-dimer-programs-targeting-b-cell-depletion-at-the-american-college-of-rheumatology-acr-convergence-2024/2024-11-13T21:36:44-08:00https://hingebio.com/2024/11/beyond-antibodies-and-car-t/2024-11-17T22:28:39-08:00https://hingebio.com/2025/01/hinge-bio-raises-30-million-series-a/2025-01-14T19:55:11-08:00https://hingebio.com/2025/05/hinge-bio-hb2198-lupus-sle-2025-poster/2025-05-23T05:52:58-07:00https://hingebio.com/2025/09/hinge-bio-expands-leadership-team-to-drive-clinical-development-of-gem-dimer-programs-and-announces-publication-in-scientific-reports/2025-09-04T03:50:09-07:00https://hingebio.com/2025/09/anti-cd19-cd20-bispecific-antibody-with-dual-fc-domains-mediates-enhanced-effector-functions-and-durable-depletion-of-memory-b-cells-in-vivo/2025-09-04T03:52:27-07:00https://hingebio.com/2025/09/hinge-bio-announces-license-and-collaboration-with-kyorin-pharmaceutical-co-ltd-for-the-development-and-commercialization-of-hb2198-in-japan-for-autoimmune-diseases/2025-09-30T16:22:47-07:00https://hingebio.com/2025/10/hinge-bio-announces-fda-clearance-of-investigational-new-drug-application-for-hb2198-a-novel-b-cell-depleting-agent-for-patients-with-systemic-lupus-erythematosus-and-lupus-nephritis/2025-10-13T06:53:25-07:00https://hingebio.com/2026/04/hinge-bio-announces-first-subject-dosed-in-phase-1-trial-of-hb2198-a-novel-b-cell-depleting-agent-for-treating-autoimmune-disease/2026-04-13T08:57:19-07:00